Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Acquired by LPL Financial LLC

LPL Financial LLC boosted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 8.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,366 shares of the company’s stock after acquiring an additional 1,510 shares during the period. LPL Financial LLC’s holdings in Amphastar Pharmaceuticals were worth $756,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Fox Run Management L.L.C. acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $688,000. KLP Kapitalforvaltning AS acquired a new position in Amphastar Pharmaceuticals during the fourth quarter worth $275,000. AXQ Capital LP purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter worth $246,000. Quantbot Technologies LP acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at $945,000. Finally, TD Private Client Wealth LLC raised its holdings in shares of Amphastar Pharmaceuticals by 22.7% in the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after buying an additional 388 shares during the period. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Price Performance

AMPH stock opened at $23.93 on Wednesday. The stock’s 50 day moving average price is $27.46 and its 200 day moving average price is $36.97. The firm has a market cap of $1.14 billion, a P/E ratio of 7.98, a PEG ratio of 2.19 and a beta of 0.79. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a 1 year low of $22.64 and a 1 year high of $53.96.

Analyst Ratings Changes

Several brokerages recently weighed in on AMPH. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Piper Sandler decreased their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Friday, March 21st.

Insider Activity

In related news, CFO William J. Peters sold 4,231 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now owns 97,363 shares of the company’s stock, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.